Notice of AGM & Publication of 2025 Annual Report

About this update from Abingdon Health Plc

  Abingdon Health plc ("Abingdon Health", the "Group" or the "Company")   Notice of Annual General Meeting &  Publication of 2025 Annual Report   York, U.K. 14 November 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid tests and med-tech, announces that its Annual General Meeting ('AGM') will be held on Wednesday 10 December 2025 at 12.00 GMT at the Company's offices at York Biotech Campus, Sand Hutton, York, YO41 1LZ, United Kingdom.   Printed copies of the Notice of the AGM and 2025 Annual Report have been posted to registered shareholders who have elected to receive paper communications and will shortly be available on the Company's website www.abingdonhealth.com .   Enquiries:     Abingdon Health plc www.abingdonhealth.com/investors/   Chris Hand, Executive   Chairman Via Walbrook PR   Tom Hayes, CFO   Zeus (Sole Broker and Nominated Adviser)   Tel:  +44 (0)20 3829 5000   Antonio Bossi / Jacob Walker (Corporate Finance)   Nick Searle/Fraser Marshall (Corporate Broking)   Walbrook PR (Media & Investor Relations)    Tel: +44 (0)20 7933 8780 or  [email protected]   Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654   About Abingdon Health plc Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.      The Group's  CDMO  expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from "idea to commercial success".  Abingdon Analytical Ltd offers performance evaluation for lateral flow and other  in vitro  diagnostic assays from its Doncaster laboratory.    Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK.  Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.    Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.   Abingdon Health's  brochure  outlines the comprehensive support the Group can now provide to its international customers.  For more information visit:  www.abingdonhealth.com .

View stock analysis, news, and events for Abingdon Health Plc